Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )

Résumé fourni par la source

Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat-to-target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict-of-interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence-level and recommendation-strength framework. The panel defined acceptable and optimal therapeutic targets using clinician-reported measures and patient-reported outcome measures. Eczema Area and Severity Index (EASI)-based thresholds and core symptom and quality-of-life instruments were supported by higher-quality evidence, whereas follow-up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat-to-target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.